+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Grass Pollen Allergy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 48 Pages
  • April 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5589940
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The latest Pharmaceutical and Healthcare disease pipeline guide Grass Pollen Allergy - Drugs In Development, 2022, provides an overview of the Grass Pollen Allergy (Immunology) pipeline landscape.

Grass pollen allergy is a reaction which occurs soon after exposure to pollen from grasses. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies.

Report Highlights


The Pharmaceutical and Healthcare latest pipeline guide Grass Pollen Allergy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Grass Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Grass Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Grass Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 7, 1 and 1 respectively.

Grass Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Grass Pollen Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Grass Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Grass Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Grass Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Grass Pollen Allergy (Immunology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Grass Pollen Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Grass Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

IntroductionReport CoverageGrass Pollen Allergy - Overview
Grass Pollen Allergy - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Grass Pollen Allergy - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Grass Pollen Allergy - Companies Involved in Therapeutics Development
  • Allergy Therapeutics Plc
  • ASIT Biotech SA
  • DC4U BV
  • H. Lundbeck AS
  • HAL Allergy BV
  • Regeneron Pharmaceuticals Inc
  • Revolo Biotherapeutics Ltd
  • Roxall Medizin GmbH
  • Worg Pharmaceuticals Hangzhou Co Ltd
Grass Pollen Allergy - Drug Profiles
  • Allergen for Grass Pollen Allergy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • dupilumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • gp-ASIT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • IRL-201104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • LuAG-09222 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Pollinex Quattro Grass - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
  • Vaccine for Grass Pollen Allergy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • Vaccine for Grass Pollen Allergy and House Dust Mite Allergy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • WP-1048 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • History of Events
Grass Pollen Allergy - Dormant ProjectsGrass Pollen Allergy - Discontinued ProductsGrass Pollen Allergy - Product Development Milestones
Featured News & Press Releases
  • May 06, 2021: Allergy Therapeutics: Completion of treatment phase in G309 study
  • Aug 26, 2020: Chronic hepatitis B: vaccine against grass pollen allergy as potential treatment
  • Nov 26, 2019: Allergy Therapeutics announces update to Grass MATA MPL phase III clinical programme
  • Jun 27, 2019: Allergy Therapeutics: Successful litigation settlement relating to PQ Grass Phase II Trial
  • Apr 25, 2019: Allergy Therapeutics provides regulatory and trading update
  • Jun 25, 2018: Allergy Therapeutics announces publication of data demonstrating long-lasting efficacy of Pollinex Quattro Grass vaccine in Immunotherapy
  • May 21, 2018: Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study
  • Feb 05, 2018: Landmark clinical study with grass pollen vaccine BM32 published
  • Jan 26, 2017: Biomay AG Reports Positive Results From A Second Phase IIb Trial With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32
  • Sep 08, 2016: Grass pollen allergy vaccine also effective against hepatitis B
  • Jun 27, 2016: Allergy Therapeutics announces findings from mEEC dose range finding study G204
  • Mar 04, 2016: Inflamax Research Announces the Successful Completion of Enrollment for the First Multi-center, Mobile Environmental Exposure Chamber (mEEC) Study
  • Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL
  • Jan 28, 2016: Biomay initiates new phase II clinical trial with grass pollen allergy vaccine BM32
  • Jun 03, 2015: Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference.
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact the Analyst
List of Tables
  • Number of Products under Development for Grass Pollen Allergy, 2022
  • Number of Products under Development by Companies, 2022
  • Products under Development by Companies, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, 2022
  • Grass Pollen Allergy - Pipeline by ASIT Biotech SA, 2022
  • Grass Pollen Allergy - Pipeline by DC4U BV, 2022
  • Grass Pollen Allergy - Pipeline by H. Lundbeck AS, 2022
  • Grass Pollen Allergy - Pipeline by HAL Allergy BV, 2022
  • Grass Pollen Allergy - Pipeline by Regeneron Pharmaceuticals Inc, 2022
  • Grass Pollen Allergy - Pipeline by Revolo Biotherapeutics Ltd, 2022
  • Grass Pollen Allergy - Pipeline by Roxall Medizin GmbH, 2022
  • Grass Pollen Allergy - Pipeline by Worg Pharmaceuticals Hangzhou Co Ltd, 2022
  • Grass Pollen Allergy - Dormant Projects, 2022
  • Grass Pollen Allergy - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Grass Pollen Allergy, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products by Targets, 2022
  • Number of Products by Stage and Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Allergy Therapeutics Plc
  • ASIT Biotech SA
  • DC4U BV
  • H. Lundbeck AS
  • HAL Allergy BV
  • Regeneron Pharmaceuticals Inc
  • Revolo Biotherapeutics Ltd
  • Roxall Medizin GmbH
  • Worg Pharmaceuticals Hangzhou Co Ltd